Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Queensland Health
Cerilliant
Accenture
Cipla
Julphar
US Department of Justice
Medtronic
Federal Trade Commission

Generated: June 25, 2018

DrugPatentWatch Database Preview

NINLARO Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Ninlaro patents expire, and what generic alternatives are available?

Ninlaro is a drug marketed by Millennium Pharms and is included in one NDA. There are nine patents protecting this drug.

This drug has two hundred and four patent family members in forty-four countries.

The generic ingredient in NINLARO is ixazomib citrate. One supplier is listed for this compound. Additional details are available on the ixazomib citrate profile page.
Summary for NINLARO
International Patents:204
US Patents:9
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 55
Clinical Trials: 19
Patent Applications: 9
DailyMed Link:NINLARO at DailyMed
Drug patent expirations by year for NINLARO
Pharmacology for NINLARO
Drug ClassProteasome Inhibitor
Mechanism of ActionProteasome Inhibitors

US Patents and Regulatory Information for NINLARO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Millennium Pharms NINLARO ixazomib citrate CAPSULE;ORAL 208462-003 Nov 20, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Millennium Pharms NINLARO ixazomib citrate CAPSULE;ORAL 208462-003 Nov 20, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Millennium Pharms NINLARO ixazomib citrate CAPSULE;ORAL 208462-003 Nov 20, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Millennium Pharms NINLARO ixazomib citrate CAPSULE;ORAL 208462-003 Nov 20, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for NINLARO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,915,236 Proteasome inhibitors and methods of using the same ➤ Sign Up
8,772,536 Proteasome inhibitors ➤ Sign Up
9,175,018 Boronate ester compounds and pharmaceutical compositions thereof ➤ Sign Up
8,058,262 Proteasome inhibitors and methods of using the same ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for NINLARO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0871 Netherlands ➤ Sign Up PRODUCT NAME: IXAZOMIB EN FARMACEUTISCH AANVAARDBARE ZOUTEN EN ESTERS DAARVAN, ZOALS IXAZOMIBCITRAAT; REGISTRATION NO/DATE: EU/1/16/1094 20161123
0170014 00227 Estonia ➤ Sign Up PRODUCT NAME: IKSASOMIIB;REG NO/DATE: EU/1/16/1094 23.11.2016
2017000025 Germany ➤ Sign Up PRODUCT NAME: LXAZOMIB UND DESSEN PHARMAZEUTISCH VERTRAEGLICHE SALZE UND ESTER WIE LXAZOMIBCITRAT; REGISTRATION NO/DATE: EU/1/16/1094 20161121
2017 00014 Denmark ➤ Sign Up PRODUCT NAME: IXAZOMIB OG FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER IXAZOMIBCITRAT; REG. NO/DATE: EU/1/16/1094 20161123
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Express Scripts
Argus Health
Healthtrust
Cipla
Mallinckrodt
Deloitte
Federal Trade Commission
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.